---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-279962"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2021-09-23T23:59:59+00:00"
generated_at: "2026-06-29T01:49:11.839980+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences reports SGT-001 1.5-year data showing functional benefit in DMD patients 4-6

## Summary
- NSAA mean decrease 1.7 pts vs expected 4.5 pt decline from natural history; difference +2.8 pts.
- 6MWT mean increase 15.3 meters vs expected 63.5-meter decline; difference +78.8 meters.
- Percent predicted FVC improved 4.1% vs expected 7.5% decline; difference +11.6%.
- PODCI global, sports, transfer, upper-body scales showed sustained improvements at 1.5 years.
- No new drug-related safety findings in patients with post-dosing periods up to 3.5 years.

## SEC filing metadata
- accession: 0001193125-21-279962
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2021-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312521279962/0001193125-21-279962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312521279962/d200279d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-279962
- JSON: https://secwatch.observer/filing/0001193125-21-279962.json
- Plain text: https://secwatch.observer/filing/0001193125-21-279962.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.